Published in Antimicrob Agents Chemother on June 23, 2014
Structure of the E. coli ribosome-EF-Tu complex at <3 Å resolution by Cs-corrected cryo-EM. Nature (2015) 1.83
High-resolution structure of the Escherichia coli ribosome. Nat Struct Mol Biol (2015) 1.14
Klebsazolicin inhibits 70S ribosome by obstructing the peptide exit tunnel. Nat Chem Biol (2017) 0.82
Structures of the orthosomycin antibiotics avilamycin and evernimicin in complex with the bacterial 70S ribosome. Proc Natl Acad Sci U S A (2016) 0.77
A combined cryo-EM and molecular dynamics approach reveals the mechanism of ErmBL-mediated translation arrest. Nat Commun (2016) 0.76
InterRNA: a database of base interactions in RNA structures. Nucleic Acids Res (2015) 0.75
Toxins MazF and MqsR cleave Escherichia coli ribosomal RNA precursors at multiple sites. RNA Biol (2016) 0.75
Ribosomal Antibiotics: Contemporary Challenges. Antibiotics (Basel) (2016) 0.75
Madumycin II inhibits peptide bond formation by forcing the peptidyl transferase center into an inactive state. Nucleic Acids Res (2017) 0.75
Structural insights of lincosamides targeting the ribosome of Staphylococcus aureus. Nucleic Acids Res (2017) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr (2010) 108.52
XDS. Acta Crystallogr D Biol Crystallogr (2010) 67.46
The complete atomic structure of the large ribosomal subunit at 2.4 A resolution. Science (2000) 28.25
Structures of the bacterial ribosome at 3.5 A resolution. Science (2005) 12.63
Construction and fine mapping of recombinant plasmids containing the rrnB ribosomal RNA operon of E. coli. Plasmid (1981) 9.00
Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother (2003) 7.09
Antibiotic resistance mutations in 16S and 23S ribosomal RNA genes of Escherichia coli. Nucleic Acids Res (1984) 3.94
Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell (2005) 3.46
Structures of five antibiotics bound at the peptidyl transferase center of the large ribosomal subunit. J Mol Biol (2003) 2.98
Structures of the ribosome in intermediate states of ratcheting. Science (2009) 2.96
Antibiotics of the virginiamycin family, inhibitors which contain synergistic components. Microbiol Rev (1979) 2.65
Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat Rev Microbiol (2014) 2.41
Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae. Antimicrob Agents Chemother (2001) 2.22
Streptogramins, oxazolidinones, and other inhibitors of bacterial protein synthesis. Chem Rev (2005) 1.97
An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin. Antimicrob Agents Chemother (2002) 1.79
Site-specific mutations in the 23S rRNA gene of Helicobacter pylori confer two types of resistance to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob Agents Chemother (1998) 1.76
Antibiotic discovery in the twenty-first century: current trends and future perspectives. J Antibiot (Tokyo) (2010) 1.74
Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species. Antimicrob Agents Chemother (2003) 1.70
Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramins dalfopristin and quinupristin. BMC Biol (2004) 1.68
Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother (1997) 1.54
In-vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500. J Antimicrob Chemother (1992) 1.49
Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob Agents Chemother (2009) 1.29
The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination. J Antimicrob Chemother (1992) 1.26
Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli. Antimicrob Agents Chemother (2005) 1.22
Synergy assessed by checkerboard. A critical analysis. Diagn Microbiol Infect Dis (1993) 1.16
A comparison of a new oral streptogramin XRP 2868 with quinupristin-dalfopristin against antibiotic-resistant strains of haemophilus influenzae, Staphylococcus aureus, and Streptococcus pneumoniae. Curr Microbiol (2005) 0.95
Synergistic interaction of the streptogramins with the ribosome. Eur J Biochem (1977) 0.95
Novel rapidly diversifiable antimicrobial RNA polymerase switch region inhibitors with confirmed mode of action in Haemophilus influenzae. J Bacteriol (2012) 0.89
In vitro activity of an oral streptogramin antimicrobial, XRP2868, against gram-positive bacteria. Antimicrob Agents Chemother (2005) 0.89
A spectrofluorimetric study of the interaction between virginiamycin S and bacterial ribosomes. Mol Gen Genet (1978) 0.86
Action of erythromycin and virginiamycin S on polypeptide synthesis in cell-free systems. Biochim Biophys Acta (1988) 0.85
Activity of a new oral streptogramin, XRP2868, against gram-positive cocci harboring various mechanisms of resistance to streptogramins. Antimicrob Agents Chemother (2006) 0.84
Quinupristin-dalfopristin: an overview. Pharmacotherapy (2000) 0.83
Studies on the mode of action of the streptogramin antibiotics. J Gen Microbiol (1966) 0.83
Virginiamycin as an antibiotic for poultry feeds. Nature (1962) 0.82
Inhibition of polypeptide synthesis in cell-free systems by virginiamycin S and erythromycin. Evidence for a common mode of action of type B synergimycins and 14-membered macrolides. Biochim Biophys Acta (1988) 0.82
Effects of the biological backbone on DNA-protein stacking interactions. Phys Chem Chem Phys (2009) 0.81
NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA. Curr Opin Investig Drugs (2010) 0.79
Inhibitory action of virginiamycin components on cell-free systems for polypeptide formation from Bacillus subtilis. Arch Microbiol (1983) 0.76